Literature DB >> 9041392

Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes.

G J Doellgast1, J E Brown, J A Koufman, C L Hatheway.   

Abstract

The measurement of chicken and human antibodies to Clostridium botulinum neurotoxins A, B, and E was accomplished by affinity isolation of complexes containing these antibodies. By this approach, a mixture of toxin with the test antibody, fluoresceinated antibody, and enzyme (Russell's viper venom factor X activator)-labeled antibody is allowed to form a complex in solution phase. This complex is then bound to a matrix containing antifluorescein antibody. All components not bound to the matrix are washed off, and the complex is isolated intact by elution with fluorescein, which competes with the complex for binding to the antifluorescein matrix. The eluted complex is then bound to a matrix which specifically binds the test antibody (anti-chicken immunoglobulin Y [IgY] or anti-human IgG), and the bound complex is measured by using the enzyme label. Using this approach, we were able to measure as little as 1 ng of specific antibody per ml from affinity-isolated, monospecific chicken antibody preparations and to measure antibody specifically from IgY fractions of monospecific chicken antibody preparations. Human antibodies from subjects immunized with pentavalent toxoid preparations were detectable at dilutions as great as 24,300-fold, and undiluted serum from most control subjects showed no measurable antibody. Antibody was also measured in 65 subjects who were receiving preparations of neurotoxin A (BOTOX) for the treatment of spastic disorders. Eighteen of them had toxin-specific antibody reactive with toxin B, and two of them had toxin-specific antibody reactive with toxin A. The two patients having antibody to toxin A were refractory to treatment with this toxin. This approach of isolation of hapten-labeled immune complexes under nondenaturing conditions with hapten is broadly applicable to the specific measurement of antibodies present at very low concentrations in serum.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041392      PMCID: PMC229630          DOI: 10.1128/jcm.35.3.578-583.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Botulism immune globulin for infant botulism arrives--one year and a Gulf War later.

Authors:  P J Schwarz; S S Arnon
Journal:  West J Med       Date:  1992-02

2.  Fluorescein: a complete antigenic group.

Authors:  E W Voss; W Eschenfeldt; R T Root
Journal:  Immunochemistry       Date:  1976-05

3.  Enzyme-linked immunosorbent assay-enzyme-linked coagulation assay for detection of antibodies to Clostridium botulinum neurotoxins A, B, and E and solution-phase complexes.

Authors:  G J Doellgast; M X Triscott; G A Beard; J D Bottoms
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

Review 4.  Therapeutic uses of botulinum toxin (Botox).

Authors:  L W Epperson
Journal:  Ala Med       Date:  1995 Nov-1996 Jan

Review 5.  Kinetic measurements of molecular interactions by spectrofluorometry.

Authors:  E W Voss
Journal:  J Mol Recognit       Date:  1993-06       Impact factor: 2.137

6.  Enzyme-linked immunosorbent assay and enzyme-linked coagulation assay for detection of Clostridium botulinum neurotoxins A, B, and E and solution-phase complexes with dual-label antibodies.

Authors:  G J Doellgast; G A Beard; J D Bottoms; T Cheng; B H Roh; M G Roman; P A Hall; M X Triscott
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

7.  Preparation, measurement and possible use of human antitoxin against Cl. botulinum A, B, and E toxins.

Authors:  E Habermann; S Bernáth
Journal:  Med Microbiol Immunol       Date:  1975-07-02       Impact factor: 3.402

8.  In vitro assays for botulinum toxin and antitoxins.

Authors:  C Shone; N Appleton; P Wilton-Smith; P Hambleton; N Modi; S Gatley; J Melling
Journal:  Dev Biol Stand       Date:  1986

9.  Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.

Authors:  P E Greene; S Fahn
Journal:  Mov Disord       Date:  1993-10       Impact factor: 10.338

10.  Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay.

Authors:  L S Siegel
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

View more
  3 in total

1.  Evaluation of lateral-flow Clostridium botulinum neurotoxin detection kits for food analysis.

Authors:  Shashi K Sharma; Brian S Eblen; Robert L Bull; Donald H Burr; Richard C Whiting
Journal:  Appl Environ Microbiol       Date:  2005-07       Impact factor: 4.792

Review 2.  Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.

Authors:  David P Figgitt; Stuart Noble
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Hapten mediated display and pairing of recombinant antibodies accelerates assay assembly for biothreat countermeasures.

Authors:  Laura J Sherwood; Andrew Hayhurst
Journal:  Sci Rep       Date:  2012-11-12       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.